Inmune Bio Stock Investor Sentiment

INMB Stock  USD 9.22  0.16  1.77%   
About 56% of all INmune Bio's investors are looking to take a long position. The analysis of the overall investor sentiment regarding INmune Bio suggests that some traders are interested. The current market sentiment, together with INmune Bio's historical and current headlines, can help investors time the market. In addition, many technical investors use INmune Bio stock news signals to limit their universe of possible portfolio assets.
  
over a month ago at gurufocus.com         
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt
Gurufocus Stories at Macroaxis
over a month ago at news.google.com         
Inmune Bio Announces Stock Options and Leadership Changes - TipRanks
Google News at Macroaxis
over a month ago at www.macroaxis.com         
Acquisition by Ganjei James Kelly of 32500 shares of INmune Bio at 5.05 subject to Rule 16b-3
Macroaxis News
over a month ago at finance.yahoo.com         
OmniScience and INmune Bio Partner for Alzheimers Trial
Yahoo News
over a month ago at finance.yahoo.com         
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimers Trial with Vivo, a N...
Yahoo News
over a month ago at businesswire.com         
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimers Trial with Vivo, a N...
businesswire News
over a month ago at finance.yahoo.com         
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimers Trial with Vivo, a N...
Yahoo News
over a month ago at gurufocus.com         
OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimers Trial with ...
Gurufocus Stories at Macroaxis
over two months ago at news.google.com         
INmune Bio Trading 1.7 percent Higher - Whats Next - MarketBeat
Google News at Macroaxis
over two months ago at news.google.com         
Scotiabank Initiates Coverage of INmune Bio with Sector Outperform Recommendation - MSN
Google News at Macroaxis
over two months ago at news.google.com         
INmune Bio stock hits 52-week low at 4.76 amid market challenges - Investing.com
Google News at Macroaxis
over two months ago at finance.yahoo.com         
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimers Dise...
Yahoo News
over two months ago at globenewswire.com         
INmune Bio Inc. Announces Final Enrollment of 208 Patients in Phase 2 Trial in Early Alzheimers Dise...
Macroaxis News: globenewswire.com
over three months ago at finance.yahoo.com         
INmune Bio Third Quarter 2024 Earnings US0.60 loss per share
Yahoo News
over three months ago at simplywall.st         
Is INmune Bio Using Debt In A Risky Way?
Simply Wall St News at Macroaxis
Far too much social signal, news, headlines, and media speculation about INmune Bio that are available to investors today. That information is available publicly through INmune media outlets and privately through word of mouth or via INmune internal channels. However, regardless of the origin, that massive amount of INmune data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of INmune Bio news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of INmune Bio relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to INmune Bio's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive INmune Bio alpha.

INmune Bio Performance against Dow Jones

 Price Growth (%)  
       Timeline  

Complementary Tools for INmune Stock analysis

When running INmune Bio's price analysis, check to measure INmune Bio's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy INmune Bio is operating at the current time. Most of INmune Bio's value examination focuses on studying past and present price action to predict the probability of INmune Bio's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move INmune Bio's price. Additionally, you may evaluate how the addition of INmune Bio to your portfolios can decrease your overall portfolio volatility.
Crypto Correlations
Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins
Premium Stories
Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Top Crypto Exchanges
Search and analyze digital assets across top global cryptocurrency exchanges
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Headlines Timeline
Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency